Therapeutic effect of transcatheter arterial chemoembolization combined with thalidomide or sorafenib in treatment of unresectable primary liver cancer: a comparative analysis

Zheng Kang; He MengGuo; Wang ZhiXiang

doi:10.3969/j.issn.1001-5256.2016.05.017

Issue 5

May 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(5): 899-903

PDF( 1795 KB)

Therapeutic effect of transcatheter arterial chemoembolization combined with thalidomide or sorafenib in treatment of unresectable primary liver cancer: a comparative analysis

DOI: 10.3969/j.issn.1001-5256.2016.05.017

Department of Hepatobiliary Surgery, 215 Hospital of Nuclear Industry of Shaanxi Province

Published Date: 2016-05-20

Abstract

Abstract

Objective To investigate the therapeutic effect and adverse effects of transcatheter arterial chemoembolization( TACE) combined with thalidomide or sorafenib in the treatment of unresectable primary liver cancer. Methods A total of 102 patients who underwent TACE combined with thalidomide or sorafenib in 215 Hospital of Nuclear Industry of Shaanxi Province from January 2012 to August 2013 were enrolled and divided into TACE- thalidomide group( 49 patients) and TACE- sorafenib group( 53 patients). The short- term outcome,long- term outcome,changes in related indices,and adverse events were evaluated. The independent- samples t- test was applied for comparison of continuous data between groups,and the paired t- test was applied for comparison of continuous data within one group; the chi- square test was applied for comparison of categorical data between groups; the survival curve was used for survival analysis,and the log-rank test was applied for survival comparison. Results The indices of short- term outcome,objective response rate and disease control rate,showed no significant differences between the two groups. The 2- year survival showed a significant difference between the two groups( χ2=4. 692,P = 0. 03). The log- rank test showed that overall survival time and median progression- free survival time showed significant differences between the two groups( χ2= 8. 267 and 6. 896,P = 0. 004 and 0. 009). After treatment,alpha- fetoprotein( AFP) and gamma- glutamyl transpeptidase( GGT) showed significant differences between the two groups( t = 2. 035 and 2. 843,P = 0. 038 and 0. 025). The incidence rates of nausea / vomiting,dizziness / headache,rash / desquamation,and increased blood pressure showed significant differences between the two groups( all P < 0. 05). Conclusion TACE combined with thalidomide has the same short- term therapeutic effect as TACE combined with sorafenib and can improve the patient's long- term outcome and significantly reduce the levels of AFP and GGT,but it has high incidence of nausea / vomiting and dizziness / headache.
- liver neoplasms,
- chemoembolization,therapeutic,
- thalidomide,
- sorafeni

FullText(HTML)

References(19)

References

[1]BHAYANI NH,JIANG Y,HAMED O,et al.Advances in the pharmacologic treatment of hepatocellular carcinoma[J].Curr Clin Pharmacol,2015,10(4):299-304.

[2]GE JB,XU YJ.Internal medicine[M].8th.Beijing:People's Medical Publishing House,2013:429.(in Chinese)葛均波,徐永健.内科学[M].8版.北京:人民卫生出版社,2013:429.

[3]YANG XF,LONG XD.Research advances in recurrence and metastasis of primary liver cancer[J].Henan J Surg,2012,18(2):80-83.(in Chinese)杨显富,龙先德.原发性肝癌复发转移的研究进展综述[J].河南外科学杂志,2012,18(2):80-83.

[4]YE YJ,SHEN ZL,WANG S.Therapeutic concept and strategy of metastatic liver cancer[J].Chin J Oper Proc Gen Surg:Electronic Edition,2014,8(1):26-29.(in Chinese)叶颖江,申占龙,王杉.转移性肝癌的治疗理念和策略[J].中华普外科手术学杂志:电子版,2014,8(1):26-29.

[5]Ministry of Health of the People's Republic of China.Diagnosis,management,and treatment of hepatocellular carcinoma(V2011)[J].J Clin Hepatol,2011,27(11):1141-1159.(in Chinese)中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志,2011,27(11):1141-1159.

[6]GAO S,ZHU X,YANG RJ,et al.TACE combined with hepatic arterial infusion chemotherapy using oxaliplatin,5-fluorouracil and folinic acid for intermediate and advanced hepatocellular carcinomas[J].J Intervent Radiol,2012,21(5):377-383.(in Chinese)高嵩,朱旭,杨仁杰,等.TACE联合奥沙利铂、氟尿嘧啶、亚叶酸钙肝动脉化疗治疗中晚期原发性肝癌[J].介入放射学杂志,2012,21(5):377-383.

[7]DING J,DAI X,MENG XY,et al.Research advances in response evaluation criteria in solid tumors[J].Chin J Clin Oncol Rehabil,2015,22(9):1150-1152.(in Chinese)丁婕,戴旭,孟宪运,等.实体瘤疗效评价标准的研究进展[J].中国肿瘤临床与康复,2015,22(9):1150-1152.

[8]LAN CH,WANG CY.Progress of TACE for primary liver cancer[J].Curr Physician,2009,15(23):500-502.(in Chinese)兰春虎,王常友.原发性肝癌TACE治疗进展[J].当代医学,2009,15(23):500-502.

[9]COLOMBO M,SANGIOVANNI A.Treatment of hepatocellular carcinoma:beyond international guidelines[J].Liver Int,2015,35(1):129-138.

[10]LEY AM,CHAU CH,FIGG WD.Structural studies reveal thalidomide's mechanism of action and clinical effects:crystal clear or clearly complexed?[J].Cancer Biol Ther,2015,16(1):19-20.

[11]YU J,LIU F,SUN Z,et al.The enhancement of radiosensitivity in human esophageal carcinoma cells by thalidomide and its potential mechanism[J].Cancer Biother Radiopharm,2011,26(2):219-227.

[12]GIRGIS E,MAHONEY J,DARLING-REED S,et al.Arsenic trioxde enhance the cytotoxic effect of thalidomide in a KG-la human acute mylogenous leukemia cell line[J].Oncol lett,2010,1(3):473-479.

[13]PAN JQ,LU GP,YU ZJ.Thalidomide on anti-tumor research[J].Chin J Cancer Prev Treat,2012,19(7):552-555.(in Chinese)潘骥群,鲁光平,于志坚.沙利度胺抗肿瘤的研究进展[J].中华肿瘤防治杂志,2012,19(7):552-555.

[14]NISHIDA N,KITANO M,SAKURAI T,et al.Molecular mechanism and prediction of sorafenib chemoresistance in human hepatocellular carcinoma[J].Dig Dis,2015,33(6):771-779.

[15]ZHANG HJ,GUO WD.Research advances in sorafenib in treatment of tumors[J].Chin J Clinicians:Electronic Edition,2013,7(1):258-260.(in Chinese)张惠洁,郭卫东.索拉菲尼在肿瘤治疗中的研究进展[J].中华临床医师杂志:电子版,2013,7(1):258-260.

[16]YANG M,QI XS,HAN GH.Sorafenib-related adverse events in treatment of hepatocellular carcinoma[J].J Clin Hepatol,2014,30(3):278-281.(in Chinese)杨曼,祁兴顺,韩国宏.索拉菲尼在肝癌治疗中的不良反应[J].临床肝胆病杂志,2014,30(3):278-281.

[17]CHANG BX,XIN SJ.Recent advances in research on alpha-fetoprotein and its clinical application[J].World Chin J Dig,2010,18(6):576-580.(in Chinese)常彬霞,辛绍杰.甲胎蛋白及其临床应用研究进展[J].世界华人消化杂志,2010,18(6):576-580.

[18]ZENG YL,MAO HN.The relationship between changes and prognosis of serum AFP,AKP,GGT in hepatocellular carcinoma after transcatheter hepatic arterial chemoembolization[J].China Trop Med,2011,11(11):1389-1405.(in Chinese)曾颖玲,毛惠南.血清AFP、AKP和GGT在肝癌化疗栓塞后的改变与预后的关系[J].中国热带医学,2011,11(11):1389-1405.

[19]WAN XH,LU XF.Diagnostics[M].8th ed.Beijing:People's Medical Publishing House,2013:366-372.(in Chinese)万学红,卢雪峰.诊断学[M].8版.北京:人民卫生出版社,2013:366-372.

Relative Articles

[1]	Chuanfu QIN, Yali ZHAO, Lijuan LONG, Hua QIU. Mechanism of cytotoxic T lymphocyte－derived exosomes inhibiting hepatic stellate cell activation[J]. Journal of Clinical Hepatology, 2023, 39(10): 2340-2347. doi: 10.3969/j.issn.1001-5256.2023.10.011
[2]	Tianyu LI, Huimin YAN. Mechanism of action of forkhead box transcription factors in hepatocellular carcinoma and their prospects as treatment targets[J]. Journal of Clinical Hepatology, 2021, 37(4): 931-934. doi: 10.3969/j.issn.1001-5256.2021.04.044
[3]	Xiaoke RAN, Xinju CHEN, Yunxia ZHAO, Xin ZHANG, He YANG, Yiyao SUN, Xiaoqi CHEN. Expression and clinical significance of forkhead box A2 and forkhead box J2 in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(6): 1342-1347. doi: 10.3969/j.issn.1001-5256.2021.06.025
[4]	Wang ShanShan, Zhang QingShan, Zhao SuXian, Kong LingBo, Ji Lei, Kong Li. The immunoregulatory effect of tumor necrosis factor-alpha-induced protein 8-like 2 in different liver diseases[J]. Journal of Clinical Hepatology, 2020, 36(2): 460-463. doi: 10.3969/j.issn.1001-5256.2020.02.050
[5]	Li Tian, Wu Yan, Ji Ting, Jin ZhenXiao. Role of FOXO1/3 in the pathogenesis of hepatic fibrosis[J]. Journal of Clinical Hepatology, 2019, 35(8): 1842-1846. doi: 10.3969/j.issn.1001-5256.2019.08.043
[6]	Kong Li, Zhang YuZhuo, Jin Meng, Wang ShanShan, Du JingHua, Zhang YuGuo, Wang RongQi, Ren WeiGuang, Nan YueMin. mRNA expression and significance of tumor necrosis factor-alpha-induced protein 8-like 2 and forkhead box P3 in peripheral blood mononuclear cells in patients with primary liver cancer[J]. Journal of Clinical Hepatology, 2019, 35(12): 2721-2724. doi: 10.3969/j.issn.1001-5256.2019.12.016
[7]	Li Yu, Zhang Hong, Li Zhu, Liu QingE, Wang Lu, Zhang Dan, Cao NingJia, Su Li. Influence of the Notch signaling pathway on CD8⁺T lymphocyte function in patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2018, 34(2): 287-291. doi: 10.3969/j.issn.1001-5256.2018.02.014
[8]	Guo FeiBo, Wu JunZhu, Ai LiMing, Song Ying. Clinical significance of Th17/Treg and associated cytokines in peripheral blood in chronic hepatitis C patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2017, 33(3): 479-484. doi: 10.3969/j.issn.1001-5256.2017.03.017
[9]	Kong Li, Jin Meng, Zhao SuXian. Role of tumor necrosis factor- alpha- induced protein 8-like 2 in development and progression of liver and gastrointestinal tumors[J]. Journal of Clinical Hepatology, 2017, 33(1): 175-179. doi: 10.3969/j.issn.1001-5256.2017.01.041
[10]	Guo FeiBo. Change in peripheral blood CD4~+ regulatory T cells and its association with antiviral effect in patients with chronic hepatitis C[J]. Journal of Clinical Hepatology, 2016, 32(12): 2317-2321. doi: 10.3969/j.issn.1001-5256.2016.12.017
[11]	Liu Mei, Zhang LiLi, Chen Ming, Pan XiuCheng, Li Li. The expression of suppressor of cytokine signaling-1 mRNA in the peripheral blood mononuclear cells of patients with chronic hepatitis B infection[J]. Journal of Clinical Hepatology, 2011, 27(5): 500-502.
[12]	Chen RuiLin, Lin ShuMei, Zhang ShuLin, Ye Feng, Zhang Xi, Zhao YingRen. Detection of the replicative state of HBV in peripheral blood mononuclear cells by improving PCR[J]. Journal of Clinical Hepatology, 2008, 24(5): 328-331.
[14]	Cui Fang, Wang DongPing. Detection of HBV DNA in periphereal blood mononuclear cells of patients with hepatitis B by FQ-FCR and its significance[J]. Journal of Clinical Hepatology, 2006, 22(2): 97-98.
[16]	Zhang Biao, Sui Tao, Yu XiuYing, Cao YongXian, Yao Yuan, He Hong. Significance of detecting apoptosis of PBMC and cytokine of supernatant induced by PHA in chronic hepatitis B[J]. Journal of Clinical Hepatology, 2004, 20(3): 138-140.
[17]	Song MinNing, Luo MeiLan, Huang WenQi, Min Feng. The study of levels of IL-10, IL-12 and γ-IFN in the culture medium of peripheral blood mononuclear cells from HBeAg positive chronic asymptomatic HBV patient[J]. Journal of Clinical Hepatology, 2003, 19(3): 176-177.
[19]	Zhang KaiYu, Cai YanJun, Wang Feng, Xu Chang, Lu: MeiDe. Study on Relationship between Detection of Hepatitis B Virus Replicative Intermediates RNA and Hepatitis B Virus DNA in Peripheral Blood Mononuclear Cells in Patients with Hepatitis B Virus Infection[J]. Journal of Clinical Hepatology, 2001, 17(3): 149-151.
[20]	Zhang KaiYu, Wang Feng, Lou JinFeng, Cai YanJun, Lu: MeiDe. Detection of Hepatitis B virus Replicative Intermediates RNA in Peripheral Blood Mononuclear cells in patients with Hepatitis B virus Infection and its clinical significance[J]. Journal of Clinical Hepatology, 2000, 16(2): 88-90.

Supplements(0)

Cited By

Cited by

Periodical cited type(8)

1.	王德志，胡海洋，郭长华，宋磊. 钆贝葡胺核磁共振增强与CT多期增强扫描对肝硬化伴小肝癌诊断的对比研究. 中西医结合肝病杂志. 2021(05): 449-451 .
2.	赵锦洪，彭德新，杨智利，徐仁根，刘岚，龚良庚. 普美显和马根维显MRI增强对肝硬化背景下小肝癌诊断的对比研究. 江西医药. 2021(07): 915-918 .
3.	罗竹人，汪艳，蔡琳婷，郭春英. 钆塞酸二钠增强MRI与增强CT对肝脏局灶性病变的诊断价值. 中国卫生标准管理. 2020(24): 66-70 .
4.	李艳丽，解玥，汤奉琼，马婷，赵惠菊. 肝脏特异性造影剂(钆塞酸二钠)的应用体会. 智慧健康. 2020(33): 85-86 .
5.	沈丽荣，张立云，戴灼南. 肝胆期钆塞酸二钠磁共振动态增强扫描在肝硬化结节与小肝癌的鉴别诊断中的应用价值. 广州医科大学学报. 2019(02): 44-47 .
6.	陈翔，王苇. 普美显动态增强联合DWI对强化特征不典型肝癌和肝内复发灶的诊断价值. 临床医学研究与实践. 2018(21): 150-151 .
7.	董丽伟，王飞，罗是是，赵应满，陈峰，李建军. 3.0T磁共振钆塞酸二钠增强扫描对肝硬化患者肝脏再生结节良恶性质的鉴别诊断价值. 中国医药导报. 2018(31): 127-130 .
8.	王莉莉，李俊峰，窦郁，郭顺林，雷军强. MR功能成像对肝细胞癌微血管侵犯的评估价值. 临床肝胆病杂志. 2018(12): 2681-2684 . 本站查看

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2771) PDF downloads(429)

Therapeutic effect of transcatheter arterial chemoembolization combined with thalidomide or sorafenib in treatment of unresectable primary liver cancer: a comparative analysis

DOI: 10.3969/j.issn.1001-5256.2016.05.017